A case-control study of therapy of amifostine plus chemotherapy on acute myeloid leukemia consolidation / 中国综合临床

ABSTRACT

Objective To investigate the protective effect of normal hematopoietic and without causing the increase of relapse rate of amifostine in patients with acute myeloid chemotherapy.Methods One hundred and forty-two acute myeloid leukemia(AML) patients were selected and divided into combination group(n =56) and chemotherapy alone group (n =86).Hematological toxicity and non-hematologic toxicity,response rate,duration of response of patients were prospective,non-randomized,case-control study.Results Fifty-six patients in combined group included 30 male and 26 female patients,and 18 patients in high risk stage and 32 patients in intermediate risk stage and 6 patients in low risk.The median age was (35.14 ± 14.42) year in combination group.Chemotherapy alone group included 58 male 28 female patients,and 14 patients in high risk and 64 patients in intermediate risk and 8 patients in low risk.The median age was (46.58 ± 16.99) year.There were no significant difference between two groups in terms of gender (P =0.318) and risk stage(P =0.262).But more young patients were in combination group compared with chemotherapy alone group and there was significant difference(P =0.004).In combination group,42.9％ (24 cases)patients got high Ara-C dose and 32.1％ (18 cases) patients got high HAA dose chemotherapy compared with control group (14.9％ (12 cases)and 20.9％ (18 cases)).The during periods of platelet with ＜20 × 109/L in combination was 0(0,7) day,lower than that in chemotherapy alone group (9 (4,14),P =0.01).Meanwhile the volume of platelet infusion in combination group was less than that in chemotherapy alone group and the nadir of platelet4(0(0,3) U vs.4(1,6) U,P =0.02).No statistic difference was found in two groups regarding of non-hematological side effects and the relapse rate (before and after treatment,combination group96.4％ (54/56) ; Chemotherapy alone group98.8 ％ (85/86) ; P=0.062).Conclusion Amifostine may provide protection for AML patients,can short duration of thrombocytopenia,reduce platelet transfusions,and other side effect was no significant difference.